COVID-19 Induced Cardiovascular Complications and Recent Therapeutic Advances



Abstract Views
996

Downloads
365

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Oct 10, 2021
Published Nov 13, 2021
10.24018/ejmed.2021.3.6.1099

Abstract viewed = 996 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

A global pandemic instigated by SARS-CoV-2 virus has been going strongly for almost two years. There have been almost 240 million cases with almost 5 million fatalities all over the world so far. COVID has affected almost every aspect of people’s lives halting the world in immeasurable ways. Although COVID-19 is mostly affecting the respiratory system, it is also responsible for a significant amount of cardiovascular system involvement. On one hand, it deteriorates any pre-existing cardiovascular condition, on another hand, it triggers other inflammation-facilitated acute events. They comprise of inflammatory heart disease, severe pericardial effusion, ventricular arrhythmias, endothelial dysfunction, pulmonary hypertension, heart failure, and many more. In this article, we summarize the features, management, and treatment of several important COVID-19 induced cardiovascular complications. Recent advances in the treatment of these diseases along with the justification and concerns of specific therapeutic measures are also discussed.

Keywords: Cardiovascular, management, therapeutics, COVID-19

Downloads

Download data is not yet available.

References

  1. “COVID live update: 245,121,473 cases and 4,975,150 deaths from the Coronavirus - worldometer,” Worldometers.info. [Online]. Available: https://www.worldometers.info/coronavirus/. [Accessed: 26-Oct-2021].
     Google Scholar
  2. E. A. Adeghate, N. Eid, and J. Singh, “Mechanisms of COVID-19-induced heart failure: a short review,” Heart Fail. Rev., vol. 26, no. 2, pp. 363–369, 2021.
    DOI  |   Google Scholar
  3. F. Mai, R. Del Pinto, and C. Ferri, “COVID-19 and cardiovascular diseases,” J. Cardiol., vol. 76, no. 5, pp. 453–458, 2020.
    DOI  |   Google Scholar
  4. V. Gerc, I. Masic, N. Salihefendic, and M. Zildzic, “Cardiovascular diseases (CVDs) in COVID-19 pandemic era,” Mater. Sociomed., vol. 32, no. 2, pp. 158–164, 2020.
    DOI  |   Google Scholar
  5. M. Boukhris et al., “Cardiovascular implications of the COVID-19 pandemic: A global perspective,” Can. J. Cardiol., vol. 36, no. 7, pp. 1068–1080, 2020.
    DOI  |   Google Scholar
  6. D. Atri, H. K. Siddiqi, J. P. Lang, V. Nauffal, D. A. Morrow, and E. A. Bohula, “COVID-19 for the cardiologist: Basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies,” JACC Basic Transl. Sci., vol. 5, no. 5, pp. 518–536, 2020.
    DOI  |   Google Scholar
  7. J. M. Pericàs et al., “COVID-19: from epidemiology to treatment,” Eur. Heart J., vol. 41, no. 22, pp. 2092–2112, 2020.
     Google Scholar
  8. T. Guo et al., “Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19),” JAMA Cardiol., vol. 5, no. 7, pp. 811–818, 2020.
    DOI  |   Google Scholar
  9. O. K. Abou Hassan, C. C. Sheng, T. K. M. Wang, and P. C. Cremer, “SARS-CoV-2 myocarditis: Insights into incidence, prognosis, and therapeutic implications,” Curr. Cardiol. Rep., vol. 23, no. 9, p. 129, 2021.
    DOI  |   Google Scholar
  10. CDC COVID-19 Response Team, “Severe outcomes among patients with Coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020,” MMWR Morb. Mortal. Wkly. Rep., vol. 69, no. 12, pp. 343–346, 2020.
    DOI  |   Google Scholar
  11. T. S. M. Tsang et al., “Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: Clinical profile, practice patterns, and outcomes spanning 21 years,” Mayo Clin. Proc., vol. 77, no. 5, pp. 429–436, 2002.
    DOI  |   Google Scholar
  12. M. Kermani-Alghoraishi, A. Pouramini, F. Kafi, and A. Khosravi, “Coronavirus disease 2019 (COVID-19) and severe pericardial effusion: From pathogenesis to management: A case report based systematic review,” Curr. Probl. Cardiol., no. 100933, p. 100933, 2021.
    DOI  |   Google Scholar
  13. A. Rivero, A. Aceña, M. Orejas, and R. Hernandez-Estefania, “Recurrent haemorrhagic pericardial effusion due to idiopathic pericarditis: a case report,” Eur. Heart J. Case Rep., vol. 3, no. 1, p. ytz018, 2019.
    DOI  |   Google Scholar
  14. F. Sauer, C. Dagrenat, P. Couppie, G. Jochum, and P. Leddet, “Pericardial effusion in patients with COVID-19: case series,” Eur. Heart J. Case Rep., vol. 4, no. FI1, pp. 1–7, 2020.
    DOI  |   Google Scholar
  15. K. E. Parsova, L. Pay, Y. Oflu, R. Hacıyev, and G. Çinier, “A rare presentation of a patient with COVID-19: Cardiac tamponade,” Turk Kardiyol. Dern. Ars., vol. 48, no. 7, pp. 703–706, 2020.
    DOI  |   Google Scholar
  16. M. F. Dabbagh, L. Aurora, P. D’Souza, A. J. Weinmann, P. Bhargava, and M. B. Basir, “Cardiac tamponade secondary to COVID-19,” JACC Case Rep, vol. 2, no. 9, pp. 1326–1330, 2020.
    DOI  |   Google Scholar
  17. C. Ejikeme, M. Gonzalez, S. Elkattawy, R. Alyacoub, and C. Sherer, “Subacute COVID-19 infection presenting as indolent large pericardial effusion,” Cureus, vol. 12, no. 10, p. e10769, 2020.
    DOI  |   Google Scholar
  18. A. Reddy, S. Nethercott, R. Duehmke, S. Nair, and O. Abdul-Samad, “‘dry’ pericarditis with rapid progression to tamponade as a feature of COVID-19,” European Medical Journal, 2021.
    DOI  |   Google Scholar
  19. M. Imazio et al., “Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality: Safety and potentiality,” J. Cardiovasc. Med. (Hagerstown), vol. 21, no. 9, pp. 625–629, 2020.
    DOI  |   Google Scholar
  20. F. Kafi, A. Bolourian, Z. Mojtahedi, and A. Pouramini, “High mobility group box 1 (HMGB1) in COVID-19,” J. Prev. Epidemiol., vol. 6, no. 1, pp. e11–e11, 2021.
    DOI  |   Google Scholar
  21. H. Karmouty-Quintana, R. A. Thandavarayan, S. P. Keller, S. Sahay, L. M. Pandit, and B. Akkanti, “Emerging mechanisms of pulmonary vasoconstriction in SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) and potential therapeutic targets,” Int. J. Mol. Sci., vol. 21, no. 21, p. 8081, 2020.
    DOI  |   Google Scholar
  22. S. Kache et al., “COVID-19 PICU guidelines: for high- and limited-resource settings,” Pediatr. Res., vol. 88, no. 5, pp. 705–716, 2020.
    DOI  |   Google Scholar
  23. “ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic,” Escardio.org. [Online]. Available: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance. [Accessed: 26-Oct-2021].
     Google Scholar
  24. H. M. Al-Kuraishy, A. I. Al-Gareeb, M. S. Al-Niemi, A. K. Al-Buhadily, N. A. Al-Harchan, and C. Lugnier, “COVID-19 and phosphodiesterase enzyme type 5 inhibitors,” J. Microsc. Ultrastruct., vol. 8, no. 4, pp. 141–145, 2020.
    DOI  |   Google Scholar
  25. W.-X. Feng, Y. Yang, J. Wen, Y.-X. Liu, L. Liu, and C. Feng, “Implication of inhaled nitric oxide for the treatment of critically ill COVID-19 patients with pulmonary hypertension,” ESC Heart Fail., vol. 8, no. 1, pp. 714–718, 2021.
    DOI  |   Google Scholar
  26. B. Yu, M. J. Raher, G. P. Volpato, K. D. Bloch, F. Ichinose, and W. M. Zapol, “Inhaled nitric oxide enables artificial blood transfusion without hypertension,” Circulation, vol. 117, no. 15, pp. 1982–1990, 2008.
    DOI  |   Google Scholar
  27. M. P. Nägele, B. Haubner, F. C. Tanner, F. Ruschitzka, and A. J. Flammer, “Endothelial dysfunction in COVID-19: Current findings and therapeutic implications,” Atherosclerosis, vol. 314, pp. 58–62, 2020.
    DOI  |   Google Scholar
  28. D. Wang et al., “Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China,” JAMA, vol. 323, no. 11, pp. 1061–1069, 2020.
    DOI  |   Google Scholar
  29. A. R. Akkawi and M. Ghazal, “COVID-19 and cardiac arrhythmias: A review of the literature,” Cureus, 2021.
    DOI  |   Google Scholar
  30. T.-Y. Xiong, S. Redwood, B. Prendergast, and M. Chen, “Coronaviruses and the cardiovascular system: acute and long-term implications,” Eur. Heart J., vol. 41, no. 19, pp. 1798–1800, 2020.
    DOI  |   Google Scholar
  31. M. Traebert, B. Dumotier, L. Meister, P. Hoffmann, M. Dominguez-Estevez, and W. Suter, “Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells,” Eur. J. Pharmacol., vol. 484, no. 1, pp. 41–48, 2004.
    DOI  |   Google Scholar
  32. J. Demazière, J. M. Fourcade, C. T. Busseuil, P. Adeleine, S. M. Meyer, and J. M. Saïssy, “The hazards of chloroquine self prescription in west Africa,” J. Toxicol. Clin. Toxicol., vol. 33, no. 4, pp. 369–370, 1995.
    DOI  |   Google Scholar
  33. A. Cervera, G. Espinosa, J. Font, and M. Ingelmo, “Cardiac toxicity secondary to long term treatment with chloroquine,” Ann. Rheum. Dis., vol. 60, no. 3, p. 301, 2001.
    DOI  |   Google Scholar
  34. J. Carron, Z. Sharif, H. Hussein, M. Kennedy, B. McAdam, and R. Sheahan, “Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic,” Ir. J. Med. Sci., vol. 190, no. 1, pp. 403–409, 2021.
    DOI  |   Google Scholar
  35. H. Onohuean, H. M. Al-Kuraishy, A. I. Al-Gareeb, S. Qusti, E. M. Alshammari, and G. E.-S. Batiha, “Covid-19 and development of heart failure: mystery and truth,” Naunyn. Schmiedebergs. Arch. Pharmacol., vol. 394, no. 10, pp. 2013–2021, 2021.
    DOI  |   Google Scholar
  36. F. Zhou et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” Lancet, vol. 395, no. 10229, pp. 1054–1062, 2020.
    DOI  |   Google Scholar
  37. X. Peng et al., “Promising therapy for heart failure in patients with severe COVID-19: Calming the cytokine storm,” Cardiovasc. Drugs Ther., vol. 35, no. 2, pp. 231–247, 2021.
    DOI  |   Google Scholar
  38. C. Burkard et al., “ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells,” J. Virol., vol. 89, no. 8, pp. 4434–4448, 2015.
    DOI  |   Google Scholar
  39. K. Ihenetu, R. Espinosa, R. de Leon, G. Planas, A. Perez-Pinero, and L. Waldbeser, “Digoxin and digoxin-like immunoreactive factors (DLIF) modulate the release of pro-inflammatory cytokines,” Inflamm. Res., vol. 57, no. 11, pp. 519–523, 2008.
    DOI  |   Google Scholar
  40. J. Lee et al., “Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation,” Int. Immunopharmacol., vol. 26, no. 1, pp. 103–111, 2015.
    DOI  |   Google Scholar
  41. C. Skayem and N. Ayoub, “Carvedilol and COVID-19: A potential role in reducing infectivity and infection severity of SARS-CoV-2,” Am. J. Med. Sci., vol. 360, no. 3, p. 300, 2020.
    DOI  |   Google Scholar
  42. T. Kurum, E. Tatli, and M. Yuksel, “Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy,” Tex. Heart Inst. J., vol. 34, no. 1, pp. 52–59, 2007.
     Google Scholar
  43. K. Kotfis et al., “COVID-19-the potential beneficial therapeutic effects of spironolactone during SARS-CoV-2 infection,” Pharmaceuticals (Basel), vol. 14, no. 1, p. 71, 2021.
    DOI  |   Google Scholar
  44. B. Bozkurt, I. Kamat, and P. J. Hotez, “Myocarditis with COVID-19 mRNA vaccines,” Circulation, vol. 144, no. 6, pp. 471–484, 2021.
    DOI  |   Google Scholar
  45. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat. Microbiol., vol. 5, no. 4, pp. 536–544, 2020.
    DOI  |   Google Scholar
  46. M. Marshall et al., “Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination,” Pediatrics, vol. 148, no. 3, p. e2021052478, 2021.
    DOI  |   Google Scholar
  47. B. J. Maron et al., “Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: A scientific statement from the American heart association and American college of cardiology,” J. Am. Coll. Cardiol., vol. 66, no. 21, pp. 2362–2371, 2015.
    DOI  |   Google Scholar
  48. D. B. Cines and J. B. Bussel, “SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia,” N. Engl. J. Med., vol. 384, no. 23, pp. 2254–2256, 2021.
    DOI  |   Google Scholar
  49. A. Greinacher, T. Thiele, T. E. Warkentin, K. Weisser, P. A. Kyrle, and S. Eichinger, “Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination,” N. Engl. J. Med., vol. 384, no. 22, pp. 2092–2101, 2021.
    DOI  |   Google Scholar
  50. K.-L. Muir, A. Kallam, S. A. Koepsell, and K. Gundabolu, “Thrombotic thrombocytopenia after Ad26.COV2.S vaccination,” N. Engl. J. Med., vol. 384, no. 20, pp. 1964–1965, 2021.
    DOI  |   Google Scholar
  51. I. See et al., “US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021,” JAMA, vol. 325, no. 24, pp. 2448–2456, 2021.
    DOI  |   Google Scholar
  52. K. L. Furie, M. Cushman, M. S. V. Elkind, P. D. Lyden, G. Saposnik, and American Heart Association/American Stroke Association Stroke Council Leadership, “Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia,” Stroke, vol. 52, no. 7, pp. 2478–2482, 2021.
    DOI  |   Google Scholar
  53. L. Italia et al., “COVID-19 and heart failure: From epidemiology during the pandemic to myocardial injury, myocarditis, and heart failure sequelae,” Front. Cardiovasc. Med., vol. 8, p. 713560, 2021.
    DOI  |   Google Scholar
  54. C. Huang et al., “6-month consequences of COVID-19 in patients discharged from hospital: a cohort study,” Lancet, vol. 397, no. 10270, pp. 220–232, 2021.
    DOI  |   Google Scholar
  55. B. van den Borst et al., “Comprehensive health assessment 3 months after recovery from acute Coronavirus disease 2019 (COVID-19),” Clin. Infect. Dis., vol. 73, no. 5, pp. e1089–e1098, 2021.
    DOI  |   Google Scholar
  56. V. O. Puntmann et al., “Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus disease 2019 (COVID-19),” JAMA Cardiol., vol. 5, no. 11, pp. 1265–1273, 2020.
    DOI  |   Google Scholar
  57. C. J. Daniels et al., “Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: Results from the big Ten COVID-19 Cardiac Registry: Results from the big ten COVID-19 cardiac registry,” JAMA Cardiol., vol. 6, no. 9, pp. 1078–1087, 2021.
     Google Scholar
  58. D. Brito et al., “High prevalence of pericardial involvement in college student athletes recovering from COVID-19,” JACC Cardiovasc. Imaging, vol. 14, no. 3, pp. 541–555, 2021.
    DOI  |   Google Scholar
  59. L. T. Weckbach et al., “Myocardial inflammation and dysfunction in COVID-19-associated myocardial injury,” Circ. Cardiovasc. Imaging, vol. 14, no. 1, p. e012220, 2021.
    DOI  |   Google Scholar
  60. G. Zaccone, D. Tomasoni, L. Italia, C. M. Lombardi, and M. Metra, “Myocardial involvement in COVID-19: An interaction between comorbidities and heart failure with preserved ejection fraction. A further indication of the role of inflammation,” Curr. Heart Fail. Rep., vol. 18, no. 3, pp. 99–106, 2021.
    DOI  |   Google Scholar


Most read articles by the same author(s)